Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
nonalcoholic steatohepatitis (NASH)
Biotech
Gilead culls last MASH program, 2 cancer assets
The dropped oncology assets are a DGKα inhibitor and an MCL1 inhibitor, which join a Novo-partnered MASH program in the scrap heap.
Darren Incorvaia
Aug 8, 2025 11:50am
Researchers ID potential MASH target by disrupting mouse gene
Mar 13, 2025 1:52pm
Aligos MASH prospect slashes liver fat in phase 2
Sep 19, 2024 1:00pm
Viking's MASH drug scores where Madrigal's didn't
Jun 4, 2024 1:51pm
Boehringer signs $1.3B MASH collab with RNA biotech Ochre
Apr 22, 2024 8:45am
Ascletis pulls FXR agonist from pipeline over phase 2 data
Apr 3, 2024 8:50am
